|
1
|
Gopalakrishnan V, Tao RH, Dobson T,
Brugmann W and Khatua S: Medulloblastoma development: Tumor biology
informs treatment decisions. CNS Oncol. 4:79–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan X, Matsui W, Khaki L, Stearns D, Chun
J, Li YM and Eberhart CG: Notch pathway inhibition depletes
stem-like cells and blocks engraftment in embryonal brain tumors.
Cancer Res. 66:7445–7452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolter M, Reifenberger J, Sommer C,
Ruzicka T and Reifenberger G: Mutations in the human homologue of
the Drosophila segment polarity gene patched (PTCH) in sporadic
basal cell carcinomas of the skin and primitive neuroectodermal
tumors of the central nervous system. Cancer Res. 57:2581–2585.
1997.PubMed/NCBI
|
|
4
|
Wodarz A and Nusse R: Mechanisms of Wnt
signaling in development. Annu Rev Cell Dev Biol. 14:59–88. 1998.
View Article : Google Scholar
|
|
5
|
Northcott PA, Korshunov A, Witt H,
Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins
CE, French P, et al: Medulloblastoma comprises four distinct
molecular variants. J Clin Oncol. 29:1408–1414. 2011. View Article : Google Scholar
|
|
6
|
Cho YJ, Tsherniak A, Tamayo P, Santagata
S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L,
Eberhart CG, et al: Integrative genomic analysis of medulloblastoma
identifies a molecular subgroup that drives poor clinical outcome.
J Clin Oncol. 29:1424–1430. 2011. View Article : Google Scholar :
|
|
7
|
Taylor MD, Northcott PA, Korshunov A,
Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S,
Gajjar A, et al: Molecular subgroups of medulloblastoma: The
current consensus. Acta Neuropathol. 123:465–472. 2012. View Article : Google Scholar :
|
|
8
|
Leary SE and Olson JM: The molecular
classification of medul-loblastoma: Driving the next generation
clinical trials. Curr Opin Pediatr. 24:33–39. 2012. View Article : Google Scholar :
|
|
9
|
Harris PS, Venkataraman S, Alimova I,
Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor
MD, Foreman NK, et al: Integrated genomic analysis identifies the
mitotic checkpoint kinase WEE1 as a novel therapeutic target in
medulloblastoma. Mol Cancer. 13:722014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X and Winey M: The MPS1 family of
protein kinases. Annu Rev Biochem. 81:561–585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ling Y, Zhang X, Bai Y, Li P, Wei C, Song
T, Zheng Z, Guan K, Zhang Y, Zhang B, et al: Overexpression of Mps1
in colon cancer cells attenuates the spindle assembly checkpoint
and increases aneuploidy. Biochem Biophys Res Commun.
450:1690–1695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daniel J, Coulter J, Woo JH, Wilsbach K
and Gabrielson E: High levels of the Mps1 checkpoint protein are
protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci
USA. 108:5384–5389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Janssen A, Kops GJ and Medema RH:
Targeting the mitotic checkpoint to kill tumor cells. Horm Cancer.
2:113–116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colombo R, Caldarelli M, Mennecozzi M,
Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi
L, Cucchi U, et al: Targeting the mitotic checkpoint for cancer
therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res.
70:10255–10264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Venkataraman S, Alimova I, Balakrishnan I,
Harris P, Birks DK, Griesinger A, Amani V, Cristiano B, Remke M,
Taylor MD, et al: Inhibition of BRD4 attenuates tumor cell
self-renewal and suppresses stem cell signaling in MYC driven
medulloblastoma. Oncotarget. 5:2355–2371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tyler RK, Chu ML, Johnson H, McKenzie EA,
Gaskell SJ and Eyers PA: Phosphoregulation of human Mps1 kinase.
Biochem J. 417:173–181. 2009. View Article : Google Scholar
|
|
17
|
Samkari A, White JC and Packer RJ:
Medulloblastoma: Toward biologically based management. Semin
Pediatr Neurol. 22:6–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Malumbres M and Barbacid M: Cell cycle
kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Sheikh A, Fan R, Birks D, Donson A,
Foreman NK and Vibhakar R: Inhibition of Aurora Kinase A enhances
chemosen-sitivity of medulloblastoma cell lines. Pediatr Blood
Cancer. 55:35–41. 2010.PubMed/NCBI
|
|
20
|
Harris PS, Venkataraman S, Alimova I,
Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH,
Foreman NK, et al: Polo-like kinase 1 (PLK1) inhibition suppresses
cell growth and enhances radiation sensitivity in medulloblastoma
cells. BMC Cancer. 12:802012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maachani UB, Kramp T, Hanson R, Zhao S,
Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K and
Tandle A: Targeting MPS1 enhances radiosensitization of human
glioblastoma by modulating DNA repair proteins. Mol Cancer Res.
13:852–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wengner AM, Siemeister G, Koppitz M,
Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P,
Bader B, et al: Novel Mps1 kinase inhibitors with potent antitumor
activity. Mol Cancer Ther. 15:583–592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koch A, Maia A, Janssen A and Medema RH:
Molecular basis underlying resistance to Mps1/TTK inhibitors.
Oncogene. 35:2518–2528. 2016. View Article : Google Scholar :
|
